featured
Diabetes PracticeChanger in 2015: Cardiovascular Outcomes and Diabetes
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Zinman B, Wanner C, Lachin JM, et al for the EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [published online September 17, 2015]. N Engl J Med. DOI: 10.1056/NEJMoa1504720.
- Inzucchi, S. Cardiovascular Outcomes and Type 2 Diabetes: EMPA-REG OUTCOME. PracticeUpdate. http://www.practiceupdate.com/content/cardiovascular-outcomes-and-type-2-diabetes-empa-reg-outcome/29960/12/8/3. Accessed October 14, 2015.
- Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed October 14, 2015.
- Buse JB, Ginsberg HN, Bakris GL, et al, American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.